Pharmaceuticals, Biotechnology and Life Sciences
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, has reported €73 million net loss in its audited consolidated financial results for the year ending December 31, 2021 and provided corporate updates.
Kayentis, a global provider of eCOA and Decentralized Clinical Trial solutions, has announces the launch of a fully integrated patient-centric…
Torsten Buergermeister has been appointed Chief Financial Officer (CFO) of VERAXA Biotech, based in Heidelberg, Germany.
Catalent has completed a $30 million (€27 million) project at its facility in Limoges, France, to transform the site into a European center of excellence for biopharmaceutical development, drug product fill/finish services, and packaging.
ReNeuron Group plc (AIM: RENE), a UK-based Stem Cell and Exosomes zechnologies company, announces that Dr Tim Corn and Mark Evans have resigned as Non-Executive Directors of the Company and that Martin Walton has been appointed as a Non-Executive Director, all with immediate effect.
Leica Microsystems has introduced the new Coral Cryo workflow solution. The workflow solution enables researchers to increase their success rate…
Sobi has announced that the National Medical Products Administration of China (NMPA) has approved Gamifant (emapalumab) for use in China. The indication is for treatment of adult and paediatric (newborn and older) patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy.
Ignis Therapeutics and STADA’s Britannia Pharmaceuticals Ltd. affiliate have jointly announced that two companies have signed an exclusive licensing agreement under which Ignis Therapeutics will develop and commercialize subcutaneous apomorphine for Parkinson’s disease in mainland China, Hong Kong and Macau.
Kizoo portfolio company Revel Pharmaceuticals has raised $8.4M in Seed financing. The oversubscribed round was led by Kizoo Technology Capital and Starbloom Capital with participation from Tubus LLC. The funds will support Revel as it advances its repair-based enzyme therapy pipeline towards the clinic.
AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab) is authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) and is the first antibody combination for pre-exposure prophylaxis (PrEP) against COVID-19 licensed in Great Britain.